Package Leaflet: Information for the User
Rivaroxaban 15mg film-coated tablets EFG
Rivaroxaban 20mg film-coated tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Rivaroxaban Vir contains the active substance rivaroxaban.
Rivaroxaban is used in adults to:
Rivaroxaban is used in children and adolescents under 18 years of age and with a body weight of 30 kg or more to:
Rivaroxaban belongs to a group of medications called antithrombotic agents. It works by blocking a clotting factor (factor Xa) and thus reducing the tendency of blood to form clots.
Do not take Rivaroxaban Vir
Do not take Rivaroxaban Vir and inform your doctorif any of these circumstances apply to you.
Warnings and precautions
Consult your doctor or pharmacist before starting to take rivaroxaban.
Be careful with Rivaroxaban Vir
Inform your doctorif you have any of these conditionsbefore taking rivaroxaban. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If you need surgery
Children and adolescents
Rivaroxaban tablets are not recommended in children with a body weight of less than 30kg.
There is not enough information about the use of rivaroxaban in children and adolescents for the indications in adults.
Other medications and Rivaroxaban Vir
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including those obtained without a prescription.
If any of the above circumstances apply to you, inform your doctorbefore taking rivaroxaban, as the effect of rivaroxaban may be increased. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If your doctor considers that you have a higher risk of developing a stomach or intestinal ulcer, they may recommend that you also use a preventive treatment.
If any of the above circumstances apply to you, inform your doctorbefore taking rivaroxaban, as the effect of rivaroxaban may be reduced. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
Pregnancy and breastfeeding
Do not take rivaroxaban if you are pregnant or breastfeeding. If there is any possibility that you may become pregnant, use a reliable contraceptive while taking rivaroxaban. If you become pregnant while taking this medication, inform your doctor immediately, who will decide how you should be treated.
Driving and using machines
Rivaroxaban may cause dizziness (frequent side effect) or fainting (uncommon side effect) (see section 4 "Possible side effects"). You should not drive, ride a bicycle, or use tools or machines if you are affected by these symptoms.
This medication contains lactose and sodium
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially "sodium-free".
Follow the instructions for administration of this medication exactly as indicated by your doctor. If you are in doubt, consult your doctor or pharmacist again.
You must take Rivaroxaban Vir with food.
Swallow the tablets, preferably with water.
If you have difficulty swallowing the tablet whole, consult your doctor about other ways to take rivaroxaban. The tablet can be crushed and mixed with water or apple puree, immediately before taking it. Then, take food.
If necessary, your doctor may also administer the crushed rivaroxaban tablet through a gastric tube.
What dose to take
The recommended dose is one 20 mg rivaroxaban tablet once a day.
If you have kidney problems, the dose may be reduced to one 15 mg rivaroxaban tablet once a day.
If you need to undergo a procedure to treat blocked blood vessels in your heart (called percutaneous coronary intervention - PCI with stent insertion), there is limited evidence to reduce the dose to one 15 mg rivaroxaban tablet once a day (or one 10 mg rivaroxaban tablet once a day if your kidneys do not function properly) in addition to an antiplatelet medication such as clopidogrel.
The recommended dose is one 15 mg rivaroxaban tablet twice a day for the first 3 weeks. For treatment after 3 weeks, the recommended dose is one 20 mg rivaroxaban tablet once a day.
After at least 6 months of treatment for blood clots, your doctor may decide to continue treatment with one 10 mg tablet once a day or one 20 mg tablet once a day.
If you have kidney problems and are taking one 20 mg rivaroxaban tablet once a day, your doctor may decide to reduce the treatment dose to one 15 mg rivaroxaban tablet once a day after 3 weeks if the risk of bleeding is higher than the risk of having another blood clot.
The dose of rivaroxaban depends on body weight and will be calculated by the doctor.
Take each dose of rivaroxaban with a drink (e.g., water or juice) during a meal. Take the tablets every day at approximately the same time. Consider setting an alarm to remind you.
For parents or caregivers: observe the child to ensure they take the entire dose.
Since the dose of rivaroxaban is based on body weight, it is important to attend scheduled visits with the doctor, as it may be necessary to adjust the dose as the weight changes.
Never adjust the dose of rivaroxaban on your own. Your doctor will adjust the dose if necessary.
Do not divide the tablet to try to obtain a fraction of the tablet dose. If a smaller dose is required, please use the alternative rivaroxaban oral suspension presentation.
In children and adolescents who cannot swallow whole tablets, please use rivaroxaban oral suspension.
If the oral suspension is not available, you can crush the rivaroxaban tablet and mix it with water or apple puree immediately before taking it. Take some food after taking this mixture. If necessary, your doctor may also administer the crushed rivaroxaban tablet through a gastric tube.
If you spit out the dose or vomit
Call your doctor if you spit out the dose or vomit repeatedly after taking rivaroxaban.
When to take Rivaroxaban Vir
Take the tablets every day, until your doctor tells you to stop.
Try to take the tablets at the same time every day to remember when you should take them.
Your doctor will decide how long you should continue taking the treatment.
To prevent the formation of blood clots in the brain (stroke) or in other blood vessels:
If it is necessary to normalize your heartbeat through a procedure called cardioversion, take rivaroxaban at the times indicated by your doctor.
If you forget to take rivaroxaban
If you are taking one 20 mg or one 15 mg tablet oncea day, and you forget to take a dose, take it as soon as you remember. Do not take more than one tablet in a single day to make up for a forgotten dose. Take the next tablet the next day and, after that, continue taking one tablet every day.
If you are taking one 15 mg tablet twicea day, and you forget to take a dose, take it as soon as you remember. Do not take more than two 15 mg tablets in a single day. If you forget to take a dose, you can take two 15 mg tablets at the same time, for a total of two tablets (30 mg) in a day. The next day, you should continue taking one 15 mg tablet twice a day.
If you take more Rivaroxaban Vir than you should
Call your doctor immediately if you have taken too many rivaroxaban tablets. Taking too much rivaroxaban increases the risk of bleeding.
In case of accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested
If you interrupt treatment with Rivaroxaban Vir
Do not interrupt treatment with rivaroxaban without consulting your doctor first, as rivaroxaban treats and prevents serious conditions.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Like other similar medicines to reduce blood clot formation, rivaroxaban can cause bleeding that can endanger the patient's life. Excessive bleeding can cause a sudden drop in blood pressure (shock). In some cases, the bleeding may not be evident.
Tell your doctor immediately if you or your child experience any of the following symptoms:
Your doctor may decide to keep you under closer observation or change your treatment.
The frequency of these adverse effects is very rare (up to 1 in 10,000 people).
The frequencies of severe allergic reactions are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic edema; may affect up to 1 in 100 people).
General list of possible adverse effects found in adults, children, and adolescents
Common adverse effects(may affect up to 1 in 10 people)
Uncommon adverse effects(may affect up to 1 in 100 people)
Rare adverse effects(may affect up to 1 in 1,000 people)
Frequency not known(frequency cannot be estimated from available data)
Adverse effects in children and adolescents
In general, the adverse effects observed in children and adolescents treated with Xarelto were similar to those observed in adults and their severity was mainly mild to moderate.
Adverse effects that were more frequently observed in children and adolescents:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging and on each blister or vial after "CAD" or "EXP".
The expiration date is the last day of the month indicated.
No special storage conditions are required.
Crushed tablets
Crushed tablets are stable in water or apple sauce for up to 4 hours.
Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Composition of Rivaroxaban Vir
Core of the tablet: microcrystalline cellulose, lactose monohydrate, hypromellose (2910), croscarmellose sodium, magnesium stearate, sodium lauryl sulfate.
Coating of the tablet:
Rivaroxaban Vir 15 mg: hypromellose (2910), macrogol (3350), titanium dioxide (E 171), red iron oxide (E 172).
Rivaroxaban Vir 20 mg: hypromellose (2910), macrogol (3350), red iron oxide (E 172), titanium dioxide (E 171).
Appearance of the product and package contents
Rivaroxaban Vir 15 mg
The film-coated tablets of Rivaroxaban Vir 15 mg are red, round, biconvex tablets (5.6 mm in diameter) marked with "15" on one face and smooth on the other face.
Packages containing 14, 28, 42, or 100 film-coated tablets in transparent PVC/PVDC-Aluminum blisters.
Rivaroxaban Vir 20 mg
The film-coated tablets of Rivaroxaban Vir 20 mg are dark red, round, biconvex tablets (6.5 mm in diameter) marked with "20" on one face and smooth on the other face.
Packages containing 7, 28, 30, or 100 film-coated tablets in transparent PVC/PVDC-Aluminum blisters.
Not all package sizes may be marketed.
Marketing authorization holder
Industria Química y Farmacéutica VIR, S.A.
C/Laguna 66-68-70. Polígono Industrial Urtinsa II
28923 Alcorcón (Madrid)
Spain
Manufacturer:
Saneca Pharmaceuticals a.s.
Nitrianska 100
920 27 Hlohovec
Slovak Republic
or
Adalvo Limited
Malta Life Sciences Park, Building 1,
Level 4, Sir Temi Zammit Buildings,
San Gwann
SGN 3000, Malta
Date of the last revision of this prospectus:
July 2022
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) https://www.aemps.gob.es/